GP6 and autoimmune thrombocytopenic purpura: Comparison of disease characteristics and laboratory data between ITP patients who received eltrombopag with NR at baseline and after 6 months (Table 3) showed a significant decrease in bleeding score and a significantly higher platelet count, GPVI expression and soluble GPVI.